citalopram has been researched along with Long QT Syndrome in 58 studies
Citalopram: A furancarbonitrile that is one of the serotonin uptake inhibitors used as an antidepressant. The drug is also effective in reducing ethanol uptake in alcoholics and is used in depressed patients who also suffer from TARDIVE DYSKINESIA in preference to tricyclic antidepressants, which aggravate dyskinesia.
citalopram : A racemate comprising equimolar amounts of (R)-citalopram and its enantiomer, escitalopram. It is used as an antidepressant, although only escitalopram is active.
1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile : A nitrile that is 1,3-dihydro-2-benzofuran-5-carbonitrile in which one of the hydrogens at position 1 is replaced by a p-fluorophenyl group, while the other is replaced by a 3-(dimethylamino)propyl group.
Long QT Syndrome: A condition that is characterized by episodes of fainting (SYNCOPE) and varying degree of ventricular arrhythmia as indicated by the prolonged QT interval. The inherited forms are caused by mutation of genes encoding cardiac ion channel proteins. The two major forms are ROMANO-WARD SYNDROME and JERVELL-LANGE NIELSEN SYNDROME.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Recently, both the manufacturer of citalopram and the US Food and Drug Administration have warned health care providers and patients about new information implicating drug-induced QTc interval prolongation and torsade de pointes when using citalopram in doses >40 mg/day." | 8.88 | Citalopram, QTc interval prolongation, and torsade de pointes. How should we apply the recent FDA ruling? ( Hasnain, M; Hettema, JM; Howland, RH; Kogut, C; Pandurangi, AK; Vieweg, WV; Wood, MA, 2012) |
| "Citalopram was discontinued when the QT interval shortened progressively." | 5.72 | Torsade de pointes caused by citalopram during the pacemaker battery-depletion phase: A case report. ( Sun, Z; Tao, S; Wang, J, 2022) |
| " Therefore we investigated whether there is a drug-drug interaction between tamoxifen and SRIs resulting in a prolonged QTc-interval." | 5.51 | The Risk of QTc-Interval Prolongation in Breast Cancer Patients Treated with Tamoxifen in Combination with Serotonin Reuptake Inhibitors. ( Berger, FA; Binkhorst, L; de Groot, NMS; Hussaarts, KGAM; Mathijssen, RHJ; Mathijssen-van Stein, D; Oomen-de Hoop, E; van Alphen, RJ; van Gelder, T; van Leeuwen, RWF, 2019) |
| "Acquired Long QT syndrome is a disorder caused by medications, electrolyte imbalances, and drug interactions." | 5.35 | Citalopram induced torsade de pointes, a rare life threatening side effect. ( Chareonthaitawee, P; Kanjanauthai, S; Kanluen, T, 2008) |
| " The aim of this study was to explore a fully Bayesian methodology for population pharmacokinetic analysis of data that arose from deliberate self-poisoning with citalopram." | 5.33 | The population pharmacokinetics of citalopram after deliberate self-poisoning: a Bayesian approach. ( Duffull, SB; Friberg, LE; Hackett, LP; Isbister, GK, 2005) |
| "A literature search was conducted in Pubmed, EMBASE, and Cochrane databases using the MeSH term "long QT syndrome" and key word "citalopram" on July 11, 2014." | 4.95 | Should We be Worried About QTc Prolongation Using Citalopram? A Review. ( Banh, HL; Cave, AJ; Hutton, LMJ; St-Jean, R, 2017) |
| "Recently, both the manufacturer of citalopram and the US Food and Drug Administration have warned health care providers and patients about new information implicating drug-induced QTc interval prolongation and torsade de pointes when using citalopram in doses >40 mg/day." | 4.88 | Citalopram, QTc interval prolongation, and torsade de pointes. How should we apply the recent FDA ruling? ( Hasnain, M; Hettema, JM; Howland, RH; Kogut, C; Pandurangi, AK; Vieweg, WV; Wood, MA, 2012) |
| " We report the case of a 54-year-old patient who developed QTc interval prolongation, followed by ventricular fibrillation episodes, 10 hours after admission to the ICU, in the setting of a citalopram overdose." | 3.77 | Drug monitoring of a case of citalopram overdosage. ( Coudoré, F; Liotier, J, 2011) |
| "Citalopram is a selective serotonin reuptake inhibitor (SSRI) antidepressant that is widely used in clinical practice." | 2.49 | Citalopram and cardiac toxicity. ( Cooke, MJ; Waring, WS, 2013) |
| " The proportion of patients dosed above the new limit decreased from 8 to 1% in patients ≤ 65 years and from 46 to 23% in patients > 65 years old for citalopram versus 14-5% and 47-31% for escitalopram." | 1.91 | Dear Doctor Letters regarding citalopram and escitalopram: guidelines vs real-world data. ( Bleich, S; Bridler, R; de Bardeci, M; Greil, W; Grohmann, R; Hasler, G; Kasper, S; Köberle, U; Rüther, E; Seifert, J; Stassen, H; Toto, S; Willms, J, 2023) |
| "Citalopram was discontinued when the QT interval shortened progressively." | 1.72 | Torsade de pointes caused by citalopram during the pacemaker battery-depletion phase: A case report. ( Sun, Z; Tao, S; Wang, J, 2022) |
| " This study thus aimed to develop a population pharmacokinetic (PK)/pharmacodynamic (PD) model to characterize the relationship between escitalopram concentrations and the delayed effect on QT prolongation." | 1.62 | Population pharmacokinetic/pharmacodynamic modeling of delayed effect of escitalopram-induced QT prolongation. ( Chung, JY; Kim, A; Kim, Y, 2021) |
| "Hydroxychloroquine has been widely prescribed to treat patients with COVID-19 pneumonia." | 1.62 | Torsades de pointes in SARS-CoV-2 (COVID-19) pneumonia: medicine reconciliation and careful monitoring of QTc interval may help prevent cardiac complications. ( Ali, N; Aslam, W; Lamb, CR, 2021) |
| " Therefore we investigated whether there is a drug-drug interaction between tamoxifen and SRIs resulting in a prolonged QTc-interval." | 1.51 | The Risk of QTc-Interval Prolongation in Breast Cancer Patients Treated with Tamoxifen in Combination with Serotonin Reuptake Inhibitors. ( Berger, FA; Binkhorst, L; de Groot, NMS; Hussaarts, KGAM; Mathijssen, RHJ; Mathijssen-van Stein, D; Oomen-de Hoop, E; van Alphen, RJ; van Gelder, T; van Leeuwen, RWF, 2019) |
| "The risk of arrhythmia may be increased with concomitant use of other drugs that induce QT prolongation." | 1.51 | Impact of hospital pharmacist interventions on the combination of citalopram or escitalopram with other QT-prolonging drugs. ( Beaussier, H; Bézie, Y; Chastang, A; Corny, J; Lillo-Lelouet, A; Petre, A; Phan Thi, TT; Renet, S, 2019) |
| "Although the US Food and Drug Administration (FDA) recommended upper limits for citalopram dosing in older adults due to risk of corrected-QT (QTc) prolongation, which was adopted, and extended to escitalopram by Health Canada, the scientific basis is unclear." | 1.51 | Association between citalopram, escitalopram and QTc prolongation in a real-world geriatric setting. ( Brown, HK; Crépeau-Gendron, G; Koh, S; Madan, R; Mah, L; Shorey, C; Szabuniewicz, C; Veinish, S, 2019) |
| "For citalopram, analyses were additionally restricted to a maximum dosage of 20 mg in participants aged 60 years and older." | 1.42 | Use of selective serotonin re-uptake inhibitors and the heart rate corrected QT interval in a real-life setting: the population-based Rotterdam Study. ( Aarts, N; Hofman, A; Kors, JA; Maljuric, NM; Niemeijer, MN; Noordam, R; Stricker, BH; van den Berg, ME; Visser, LE, 2015) |
| "Sudden cardiac death was recorded in five patients, and torsade de pointes was recorded in seven other patients." | 1.39 | Drug-induced long QT in adult psychiatric inpatients: the 5-year cross-sectional ECG Screening Outcome in Psychiatry study. ( Berney, P; Dayer, P; Gaspoz, JM; Gex-Fabry, M; Girardin, FR; Shah, D, 2013) |
| "3, first for a population pharmacokinetic (PK) analysis followed by a PKPD analysis." | 1.38 | Population pharmacokinetics and pharmacodynamics of escitalopram in overdose and the effect of activated charcoal. ( Duffull, S; Hackett, LP; Isbister, GK; van Gorp, F, 2012) |
| "Citalopram (CIT) is a widely used antidepressant which acts by a selective serotonin reuptake inhibition." | 1.38 | Correlation of QTc interval prolongation and serum level of citalopram after intoxication--a case report. ( Deckert, J; Pfuhlmann, B; Unterecker, S; Warrings, B, 2012) |
| "Escitalopram has a small effect on the QTc interval." | 1.38 | A question about the potential cardiac toxicity of escitalopram. ( Howland, RH, 2012) |
| "Citalopram overdose was more likely to be associated with QT higher than the nomogram compared with the other agents (difference 7." | 1.36 | Evaluation of a QT nomogram for risk assessment after antidepressant overdose. ( Bateman, DN; Graham, A; Gray, J; Howell, C; Waring, WS; Wilson, AD, 2010) |
| "Acquired Long QT syndrome is a disorder caused by medications, electrolyte imbalances, and drug interactions." | 1.35 | Citalopram induced torsade de pointes, a rare life threatening side effect. ( Chareonthaitawee, P; Kanjanauthai, S; Kanluen, T, 2008) |
| " The aim of this study was to explore a fully Bayesian methodology for population pharmacokinetic analysis of data that arose from deliberate self-poisoning with citalopram." | 1.33 | The population pharmacokinetics of citalopram after deliberate self-poisoning: a Bayesian approach. ( Duffull, SB; Friberg, LE; Hackett, LP; Isbister, GK, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 13 (22.41) | 29.6817 |
| 2010's | 39 (67.24) | 24.3611 |
| 2020's | 6 (10.34) | 2.80 |
| Authors | Studies |
|---|---|
| de Bardeci, M | 1 |
| Greil, W | 1 |
| Stassen, H | 1 |
| Willms, J | 1 |
| Köberle, U | 1 |
| Bridler, R | 1 |
| Hasler, G | 1 |
| Kasper, S | 1 |
| Rüther, E | 1 |
| Bleich, S | 1 |
| Toto, S | 1 |
| Grohmann, R | 1 |
| Seifert, J | 1 |
| Wang, J | 1 |
| Sun, Z | 1 |
| Tao, S | 1 |
| Then, MI | 2 |
| Tümena, T | 2 |
| Sledziewska, A | 2 |
| Gaßmann, KG | 2 |
| Maas, R | 2 |
| Fromm, MF | 2 |
| Akturk, G | 1 |
| Micili, SC | 1 |
| Gursoy Doruk, O | 1 |
| Hocaoglu, N | 1 |
| Akan, P | 1 |
| Ergur, BU | 1 |
| Ahmed, S | 1 |
| Kalkan, S | 1 |
| Hussaarts, KGAM | 1 |
| Berger, FA | 1 |
| Binkhorst, L | 1 |
| Oomen-de Hoop, E | 1 |
| van Leeuwen, RWF | 1 |
| van Alphen, RJ | 1 |
| Mathijssen-van Stein, D | 1 |
| de Groot, NMS | 1 |
| Mathijssen, RHJ | 1 |
| van Gelder, T | 1 |
| Kim, Y | 1 |
| Kim, A | 1 |
| Chung, JY | 1 |
| Aslam, W | 1 |
| Lamb, CR | 1 |
| Ali, N | 1 |
| Krijnsen, PJC | 1 |
| van Os, TWDP | 1 |
| Wunderink, L | 1 |
| Rector, TS | 1 |
| Ojero-Senard, A | 1 |
| Benevent, J | 1 |
| Bondon-Guitton, E | 1 |
| Durrieu, G | 1 |
| Chebane, L | 1 |
| Araujo, M | 1 |
| Montastruc, F | 1 |
| Montastruc, JL | 1 |
| Gerlach, LB | 2 |
| Kim, HM | 1 |
| Yosef, M | 1 |
| Sales, AE | 1 |
| Stano, C | 2 |
| Kales, HC | 2 |
| Zivin, K | 2 |
| Chastang, A | 1 |
| Renet, S | 1 |
| Corny, J | 1 |
| Beaussier, H | 1 |
| Petre, A | 1 |
| Lillo-Lelouet, A | 1 |
| Phan Thi, TT | 1 |
| Bézie, Y | 1 |
| Crépeau-Gendron, G | 1 |
| Brown, HK | 1 |
| Shorey, C | 1 |
| Madan, R | 1 |
| Szabuniewicz, C | 1 |
| Koh, S | 1 |
| Veinish, S | 1 |
| Mah, L | 1 |
| Lam, RW | 2 |
| Lee, TH | 1 |
| Lee, JS | 1 |
| Keller, DL | 1 |
| Vieweg, WV | 3 |
| Hasnain, M | 3 |
| Howland, RH | 5 |
| Stock, EM | 1 |
| Copeland, LA | 1 |
| Bush, RL | 1 |
| Zeber, JE | 1 |
| Pae, CU | 1 |
| Wang, SM | 1 |
| Lee, SJ | 1 |
| Han, C | 1 |
| Patkar, AA | 1 |
| Masand, PS | 1 |
| Schreffler, SM | 1 |
| Marraffa, JM | 1 |
| Stork, CM | 1 |
| Mackey, J | 1 |
| Girardin, FR | 1 |
| Gex-Fabry, M | 1 |
| Berney, P | 1 |
| Shah, D | 1 |
| Gaspoz, JM | 1 |
| Dayer, P | 1 |
| Van Asbroeck, PJ | 1 |
| Huybrechts, W | 1 |
| De Soir, R | 1 |
| Maljuric, NM | 1 |
| Noordam, R | 1 |
| Aarts, N | 1 |
| Niemeijer, MN | 1 |
| van den Berg, ME | 1 |
| Hofman, A | 1 |
| Kors, JA | 1 |
| Stricker, BH | 1 |
| Visser, LE | 1 |
| Hutton, LMJ | 1 |
| Cave, AJ | 1 |
| St-Jean, R | 1 |
| Banh, HL | 1 |
| Vincenzi, FF | 1 |
| Ray, WA | 1 |
| Chung, CP | 1 |
| Murray, KT | 1 |
| Hall, K | 1 |
| Stein, CM | 1 |
| Maust, DT | 1 |
| Chiang, C | 1 |
| Choe, HM | 1 |
| Greene, SC | 1 |
| Brooks, DE | 1 |
| Lovecchio, F | 1 |
| Scharko, AM | 1 |
| Schumacher, J | 1 |
| de Gregorio, C | 1 |
| Morabito, G | 1 |
| Cerrito, M | 1 |
| Dattilo, G | 1 |
| Oreto, G | 1 |
| Bruggisser, M | 1 |
| Rätz Bravo, A | 1 |
| Bodmer, M | 1 |
| Lugassy, DM | 1 |
| Hoffman, RS | 1 |
| Chessex, N | 1 |
| Waring, WS | 2 |
| Graham, A | 1 |
| Gray, J | 1 |
| Wilson, AD | 1 |
| Howell, C | 1 |
| Bateman, DN | 1 |
| Fayssoil, A | 1 |
| Issi, J | 1 |
| Guerbaa, M | 1 |
| Raynaud, JC | 1 |
| Heroguelle, V | 1 |
| Mohammed, R | 1 |
| Norton, J | 1 |
| Geraci, SA | 1 |
| Newman, DB | 1 |
| Koch, CA | 1 |
| Liotier, J | 1 |
| Coudoré, F | 1 |
| van Gorp, F | 1 |
| Duffull, S | 1 |
| Hackett, LP | 2 |
| Isbister, GK | 5 |
| Unterecker, S | 1 |
| Warrings, B | 1 |
| Deckert, J | 1 |
| Pfuhlmann, B | 1 |
| Hettema, JM | 1 |
| Kogut, C | 1 |
| Wood, MA | 1 |
| Pandurangi, AK | 1 |
| Cooke, MJ | 1 |
| Sheeler, RD | 1 |
| Ackerman, MJ | 1 |
| Richelson, E | 1 |
| Nelson, TK | 1 |
| Staab, JP | 1 |
| Tangalos, EG | 1 |
| Dieser, LM | 1 |
| Cunningham, JL | 1 |
| Friberg, LE | 4 |
| Duffull, SB | 4 |
| Ryysy, R | 1 |
| Sinisalo, J | 1 |
| Viitasalo, M | 1 |
| Stokes, B | 1 |
| Buckley, NA | 1 |
| Lee, C | 1 |
| Gunja, N | 1 |
| Brown, SG | 1 |
| MacDonald, E | 1 |
| Graudins, A | 1 |
| Holdgate, A | 1 |
| Kanjanauthai, S | 1 |
| Kanluen, T | 1 |
| Chareonthaitawee, P | 1 |
| Blaschke, D | 1 |
| Parwani, AS | 1 |
| Huemer, M | 1 |
| Rolf, S | 1 |
| Boldt, LH | 1 |
| Dietz, R | 1 |
| Haverkamp, W | 1 |
| Aström-Lilja, C | 1 |
| Odeberg, JM | 1 |
| Ekman, E | 1 |
| Hägg, S | 1 |
| Meuleman, C | 1 |
| Jourdain, P | 1 |
| Bellorini, M | 1 |
| Sadeg, N | 1 |
| Loiret, J | 1 |
| Guillard, N | 1 |
| Thebault, B | 1 |
| Funck, F | 1 |
| Witchel, HJ | 1 |
| Pabbathi, VK | 1 |
| Hofmann, G | 1 |
| Paul, AA | 1 |
| Hancox, JC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Escitalopram and Language Intervention for Subacute Aphasia (ELISA)[NCT03843463] | Phase 2 | 88 participants (Anticipated) | Interventional | 2021-07-18 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for citalopram and Long QT Syndrome
| Article | Year |
|---|---|
Antidepressant and QT interval prolongation, how should we look at this issue? Focus on citalopram.
Topics: Antidepressive Agents; Citalopram; Long QT Syndrome; Risk Factors; United States; United States Food | 2014 |
Should We be Worried About QTc Prolongation Using Citalopram? A Review.
Topics: Administration, Oral; Citalopram; Humans; Long QT Syndrome; Selective Serotonin Reuptake Inhibitors | 2017 |
Citalopram, QTc interval prolongation, and torsade de pointes. How should we apply the recent FDA ruling?
Topics: Adult; Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Citalopram; Death, Sudden, | 2012 |
Citalopram and cardiac toxicity.
Topics: Animals; Citalopram; Dose-Response Relationship, Drug; Heart Diseases; Humans; Long QT Syndrome; Sel | 2013 |
54 other studies available for citalopram and Long QT Syndrome
| Article | Year |
|---|---|
Dear Doctor Letters regarding citalopram and escitalopram: guidelines vs real-world data.
Topics: Aged; Citalopram; Depressive Disorder, Major; Escitalopram; Humans; Long QT Syndrome; Psychotropic D | 2023 |
Torsade de pointes caused by citalopram during the pacemaker battery-depletion phase: A case report.
Topics: Aged, 80 and over; Citalopram; DNA-Binding Proteins; Electrocardiography; Female; Humans; Long QT Sy | 2022 |
Development in Prescriptions of Contraindicated and Potentially Harmful QT Interval-Prolonging Drugs in a Large Geriatric Inpatient Cohort From 2011 to 2021.
Topics: Aged; Citalopram; Electrocardiography; Humans; Inpatients; Long QT Syndrome; Prescriptions; Risk Fac | 2023 |
Development in Prescriptions of Contraindicated and Potentially Harmful QT Interval-Prolonging Drugs in a Large Geriatric Inpatient Cohort From 2011 to 2021.
Topics: Aged; Citalopram; Electrocardiography; Humans; Inpatients; Long QT Syndrome; Prescriptions; Risk Fac | 2023 |
Development in Prescriptions of Contraindicated and Potentially Harmful QT Interval-Prolonging Drugs in a Large Geriatric Inpatient Cohort From 2011 to 2021.
Topics: Aged; Citalopram; Electrocardiography; Humans; Inpatients; Long QT Syndrome; Prescriptions; Risk Fac | 2023 |
Development in Prescriptions of Contraindicated and Potentially Harmful QT Interval-Prolonging Drugs in a Large Geriatric Inpatient Cohort From 2011 to 2021.
Topics: Aged; Citalopram; Electrocardiography; Humans; Inpatients; Long QT Syndrome; Prescriptions; Risk Fac | 2023 |
Effects of nicorandil on QT prolongation and myocardial damage caused by citalopram in rats.
Topics: Adenosine Triphosphate; Animals; Antioxidants; Citalopram; Long QT Syndrome; Male; Nicorandil; Oxida | 2023 |
The Risk of QTc-Interval Prolongation in Breast Cancer Patients Treated with Tamoxifen in Combination with Serotonin Reuptake Inhibitors.
Topics: Aged; Antidepressive Agents, Second-Generation; Antineoplastic Agents, Hormonal; Breast Neoplasms; C | 2019 |
Population pharmacokinetic/pharmacodynamic modeling of delayed effect of escitalopram-induced QT prolongation.
Topics: Asian People; Citalopram; Electrocardiography; Heart Rate; Humans; Linear Models; Long QT Syndrome | 2021 |
Torsades de pointes in SARS-CoV-2 (COVID-19) pneumonia: medicine reconciliation and careful monitoring of QTc interval may help prevent cardiac complications.
Topics: Aged; Anti-Infective Agents; Citalopram; COVID-19 Drug Treatment; Dexamethasone; Donepezil; Drug The | 2021 |
Citalopram Discontinuation More Harmful Than Gradual Dosage Reduction?
Topics: Citalopram; Electrocardiography; Humans; Long QT Syndrome; Torsades de Pointes | 2017 |
Clarifying Methods in a Study of Outcomes of Citalopram Dosage Risk Mitigation in a Veteran Population: Response to Krijnsen et al.
Topics: Citalopram; Electrocardiography; Humans; Long QT Syndrome; Risk; Torsades de Pointes; Veterans | 2017 |
A comparative study of QT prolongation with serotonin reuptake inhibitors.
Topics: Adult; Aged; Arrhythmias, Cardiac; Citalopram; Databases, Factual; Female; Fluvoxamine; Humans; Long | 2017 |
Assessing Responsiveness of Health Systems to Drug Safety Warnings.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antidepressive Agents; Citalopram; Drug Labeling; Drug P | 2018 |
Impact of hospital pharmacist interventions on the combination of citalopram or escitalopram with other QT-prolonging drugs.
Topics: Adult; Aged; Anti-Arrhythmia Agents; Antipsychotic Agents; Arrhythmias, Cardiac; Citalopram; Drug In | 2019 |
Association between citalopram, escitalopram and QTc prolongation in a real-world geriatric setting.
Topics: Aged; Arrhythmias, Cardiac; Citalopram; Electrocardiography; Electronic Health Records; Female; Heal | 2019 |
Antidepressants and QTc prolongation.
Topics: Antidepressive Agents, Second-Generation; Citalopram; Depressive Disorder; Female; Humans; Long QT S | 2013 |
An electrocardiograph should be examined in patients with a hypersensitive esophagus before a trial of citalopram.
Topics: Biomarkers; Citalopram; Controlled Clinical Trials as Topic; Electrocardiography; Esophagus; Gastroe | 2013 |
Prescribe escitalopram instead of citalopram.
Topics: Antidepressive Agents, Second-Generation; Citalopram; Drug and Narcotic Control; Female; Humans; Lon | 2013 |
The reply.
Topics: Antidepressive Agents, Second-Generation; Citalopram; Drug and Narcotic Control; Female; Humans; Lon | 2013 |
Escitalopram and QTc prolongation.
Topics: Antidepressive Agents, Second-Generation; Citalopram; Depressive Disorder; Female; Humans; Long QT S | 2013 |
Author response.
Topics: Antidepressive Agents, Second-Generation; Citalopram; Depressive Disorder; Female; Humans; Long QT S | 2013 |
Citalopram, escitalopram, and the QT interval.
Topics: Antidepressive Agents; Citalopram; Dose-Response Relationship, Drug; Humans; Long QT Syndrome; Selec | 2013 |
Datapoints: Prevalence of QT prolongation among veterans with severe mental illness.
Topics: Antidepressive Agents; Citalopram; Humans; Long QT Syndrome; Mental Disorders; Middle Aged; Prevalen | 2013 |
Sodium channel blockade with QRS widening after an escitalopram overdose.
Topics: Acetaminophen; Adolescent; Antidotes; Bradycardia; Bundle-Branch Block; Citalopram; Delayed Rectifie | 2013 |
Drug-induced long QT in adult psychiatric inpatients: the 5-year cross-sectional ECG Screening Outcome in Psychiatry study.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Case-Control Studies; Citalopram; Cross-Sectional Stu | 2013 |
Case report, aetiology, and treatment of an acquired long-QT syndrome.
Topics: Aged; Anti-Arrhythmia Agents; Antidepressive Agents; Citalopram; Drug Interactions; Humans; Long QT | 2014 |
Use of selective serotonin re-uptake inhibitors and the heart rate corrected QT interval in a real-life setting: the population-based Rotterdam Study.
Topics: Aged; Citalopram; Cross-Sectional Studies; Databases, Factual; Drug Utilization; Electrocardiography | 2015 |
Drug-induced long QT syndrome increases the risk of drowning.
Topics: Alcohol Drinking; Citalopram; Diving Reflex; Drowning; Humans; Long QT Syndrome; Methamphetamine; Mo | 2016 |
Citalopram, escitalopram: no more effective than other SSRIs, but more toxic.
Topics: Citalopram; Depressive Disorder; Humans; Long QT Syndrome; Seizures; Selective Serotonin Reuptake In | 2016 |
High-Dose Citalopram and Escitalopram and the Risk of Out-of-Hospital Death.
Topics: Adult; Aged; Ambulatory Care; Citalopram; Cohort Studies; Dose-Response Relationship, Drug; Drug The | 2017 |
Unintended Consequences of Adjusting Citalopram Prescriptions Following the 2011 FDA Warning.
Topics: Aged; Aged, 80 and over; Citalopram; Drug Labeling; Drug Prescriptions; Electrocardiography; Female; | 2017 |
Effect of activated charcoal on citalopram-induced QT prolongation.
Topics: Adult; Charcoal; Citalopram; Databases, Factual; Drug Overdose; Electrocardiography; Female; Humans; | 2008 |
Prolonged QTc interval in a 14-year-old girl with escitalopram overdose.
Topics: Adolescent; Citalopram; Drug Overdose; Female; Humans; Long QT Syndrome | 2008 |
Citalopram-induced long QT syndrome and torsade de pointes: role for concomitant therapy and disease.
Topics: Antidepressive Agents, Second-Generation; Citalopram; Depressive Disorder, Major; Diuretics; Drug Th | 2011 |
[Medication associated long QT syndrome].
Topics: Aged; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Benzodiazepines; Citalopram; D | 2009 |
In response to van Gorp F. et al. Escitalopram overdose.
Topics: Citalopram; Electrocardiography; Humans; Long QT Syndrome; Medical History Taking; Selective Seroton | 2010 |
Evaluation of a QT nomogram for risk assessment after antidepressant overdose.
Topics: Adult; Antidepressive Agents; Citalopram; Cyclohexanols; Drug Overdose; Electrocardiography; Female; | 2010 |
Torsade de pointes induced by citalopram and amiodarone.
Topics: Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Citalopram; Depressive D | 2011 |
Prolonged QTc interval due to escitalopram overdose.
Topics: Adult; Citalopram; Depressive Disorder; Drug Overdose; Electrocardiography; Female; Humans; Long QT | 2010 |
Drug monitoring of a case of citalopram overdosage.
Topics: Citalopram; Drug Monitoring; Drug Overdose; Electrocardiography; Female; Half-Life; Humans; Long QT | 2011 |
Population pharmacokinetics and pharmacodynamics of escitalopram in overdose and the effect of activated charcoal.
Topics: Adolescent; Adult; Area Under Curve; Bayes Theorem; Charcoal; Chromatography, Liquid; Citalopram; Do | 2012 |
Correlation of QTc interval prolongation and serum level of citalopram after intoxication--a case report.
Topics: Antidepressive Agents; Citalopram; Depressive Disorder, Major; Female; Humans; Long QT Syndrome; Mid | 2012 |
A critical evaluation of the cardiac toxicity of citalopram: part 1.
Topics: Aged; Citalopram; Dose-Response Relationship, Drug; Humans; Long QT Syndrome; Middle Aged; Selective | 2011 |
A question about the potential cardiac toxicity of escitalopram.
Topics: Arrhythmias, Cardiac; Citalopram; Humans; Long QT Syndrome; Selective Serotonin Reuptake Inhibitors; | 2012 |
Citalopram (Celexa) and QT interval prolongation.
Topics: Antidepressive Agents, Second-Generation; Citalopram; Drug Labeling; Humans; Long QT Syndrome; Patie | 2012 |
Considerations on safety concerns about citalopram prescribing.
Topics: Antidepressive Agents, Second-Generation; Citalopram; Depression; Dose-Response Relationship, Drug; | 2012 |
The population pharmacokinetics of citalopram after deliberate self-poisoning: a Bayesian approach.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Bayes Theorem; Biological Availab | 2005 |
Pharmacokinetic-pharmacodynamic modelling of QT interval prolongation following citalopram overdoses.
Topics: Adolescent; Adult; Age Distribution; Aged; Antidepressive Agents, Second-Generation; Charcoal; Cital | 2006 |
[Citalopram overdose poisoning in QTc interval prolongation].
Topics: Adolescent; Citalopram; Drug Overdose; Electrocardiography; Female; Finland; Follow-Up Studies; Huma | 2006 |
Application of pharmacokinetic-pharmacodynamic modelling in management of QT abnormalities after citalopram overdose.
Topics: Adolescent; Adult; Aged; Charcoal; Citalopram; Computer Simulation; Drug Overdose; Female; Guideline | 2006 |
Activated charcoal decreases the risk of QT prolongation after citalopram overdose.
Topics: Adult; Charcoal; Citalopram; Databases, Factual; Drug Overdose; Female; Humans; Long QT Syndrome; Ma | 2007 |
Citalopram induced torsade de pointes, a rare life threatening side effect.
Topics: Aged, 80 and over; Citalopram; Humans; Long QT Syndrome; Male; Torsades de Pointes | 2008 |
Torsade de pointes during combined treatment with risperidone and citalopram.
Topics: Aged; Antipsychotic Agents; Citalopram; Drug Therapy, Combination; Electrocardiography, Ambulatory; | 2007 |
Drug-induced torsades de pointes: a review of the Swedish pharmacovigilance database.
Topics: Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Age Factors; Aged; Aged, 80 and over; Ca | 2008 |
[Citalopram and Torsades de Pointes. A case report].
Topics: Antidepressive Agents, Second-Generation; Citalopram; Female; Humans; Long QT Syndrome; Middle Aged; | 2001 |
Inhibitory actions of the selective serotonin re-uptake inhibitor citalopram on HERG and ventricular L-type calcium currents.
Topics: Animals; Calcium Channels, L-Type; Cation Transport Proteins; Citalopram; Ether-A-Go-Go Potassium Ch | 2002 |